Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
251.270USD
-1.730-0.68%
Close 10-30 16:00（ET）
15.20BMarket Cap
36.19P/E TTM
About Ascendis Pharma A/S Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S Profile
Ticker SymbolASND
Company nameAscendis Pharma A/S
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJan 28
AddressTuborg Boulevard 12
CityHELLERUP
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2900
Phone4570222244
Websitehttps://ascendispharma.dk/
Ticker SymbolASND
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Company Executives of Ascendis Pharma A/S
Name
Name/Position
Position
Shareholding
Change
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Aimee Shu, M.D.
Dr. Aimee Shu, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
1.92K
--
Dr. Aimee Shu, M.D.
Dr. Aimee Shu, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
1.92K
--
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
FAQs
Who are the top five shareholders of Ascendis Pharma A/S?
The top five shareholders of Ascendis Pharma A/S are: Mr. Flemming Steen Jensen
How many institutions hold shares of Ascendis Pharma A/S (ASND)?
As of 2026Q1, 582 institutions hold shares of Ascendis Pharma A/S, with a combined market value of approximately 69.20M, accounting for 111.42% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1676383.00.
What is the biggest source of revenue for Ascendis Pharma A/S?
In 2026Q1, the Commercial sale of products business generated the highest revenue for Ascendis Pharma A/S, amounting to 314.91M and accounting for 92.82% of total revenue.